Compare UG & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | XLO |
|---|---|---|
| Founded | 1942 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9M | 41.8M |
| IPO Year | N/A | 2021 |
| Metric | UG | XLO |
|---|---|---|
| Price | $6.00 | $0.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 14.4K | ★ 522.5K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | ★ 11.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | $10,060,322.00 | ★ $31,804,000.00 |
| Revenue This Year | N/A | $589.60 |
| Revenue Next Year | N/A | $38.00 |
| P/E Ratio | $14.07 | ★ N/A |
| Revenue Growth | N/A | ★ 588.40 |
| 52 Week Low | $5.58 | $0.62 |
| 52 Week High | $11.98 | $1.70 |
| Indicator | UG | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | 35.82 |
| Support Level | $5.87 | $0.68 |
| Resistance Level | $6.10 | $0.73 |
| Average True Range (ATR) | 0.17 | 0.03 |
| MACD | 0.08 | -0.00 |
| Stochastic Oscillator | 87.49 | 2.13 |
United-Guardian Inc manufactures and markets cosmetic ingredients, pharmaceuticals, medical lubricants, and specialty industrial products. Its product portfolio includes Klensoft, Deselex, Renacidin, Lubrajel Fluid. The company's pharmaceutical products are sold to and distributed by full-line drug wholesalers throughout the United States. Its medical and specialty industrial products are sold directly by the company to the end-users of those products or, in some cases, to contract manufacturers used by some of those end users. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. It derives key revenue from the sales made in the U.S.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.